Abstract

Understanding the chemistry and biology of protein glycosylation is a major challenge in proteomics and glycomics research. Due to their pivotal role in the biosynthesis of complex oligosaccharides and glycoconjugates, protein glycosylation enzymes are targets of choice for the development of inhibitors. Glycosyltransferase and glypiation (GPI anchoring) inhibitors that are of potential therapeutic value for the treatment of diseases associated with glycosylation defects are reviewed in the light of recent developments.

Keywords: hydroxyproline, uronic acid, neuraminic acid, N-acetylgalactosamine, Congenital disorders of glycosylation, Glypiation